David Potter, SABCS 2021: Results From the I-SPY 2 Trial
Professor David Potter (Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA) discusses the results of the I-SPY 2 trial, the evaluation of tucatinib + (paclitaxel + pertuzumab + trastuzumab) in high-risk HER2 positive stage II/III breast cancer. These results were presented at the San Antonio Breast Cancer Symposium 2021.
Question: Please can you summarise the aims, design, eligibility criteria and the efficacy and safety findings of the I-SPY 2 trial?
Speaker Disclosure: David Potter reports grants from Quantum Leap Healthcare Collaborative and Seagen during the conduct of the study, as well as grants from Department of Defense, ImmunoMet Therapeutics, Pfizer, Innocrin, Takeda, Nektar Therapeutics, Roche, AstraZeneca, Spectrum Pharmaceuticals, Huya Bioscience International, Immunomedics, Gilead Sciences and National Cancer Institute of Mexico outside the submitted work.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!